Rezolute reports Q3 EPS (34c), consensus (30c)

Reports Q3 cash, cash equivalents and investments in marketable securities were $81.6 M as of March 31 compared with $118.4 M as of June 30, 2023.”In the past few months, we have been focused on global site activation and patient enrollment for sunRIZE, a pivotal Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism. We have also completed dosing of patients with diabetic macular edema for our Phase 2 multi-center clinical study of RZ402 and we expect to announce topline results from that study this month,” said Nevan Elam, Chief Executive Officer and Founder of Rezolute. “Additionally, in the U.S. we continue to have productive interactions with FDA as we work towards achieving liberalization of the partial clinical holds on sunRIZE.”